A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus

Brief description of study

The purpose of this study is to understand how safe and effective a new investigational drug elsubrutinib, upadacitinib, and elsubrutinib vs placebo for the treatment of signs and symptoms of SLE in patients with SLE. An investigational drug is one that has not been approved by the regulatory authorities in your country. These investigational drugs or “study drugs” elsubrutinib and upadacitinib (ABT-494) belongs to a group of medications called Bruton's tyrosine kinase (BTK) inhibitors and Janus kinase (JAK) inhibitors, respectively.

Clinical Study Identifier: s19-00271
ClinicalTrials.gov Identifier: NCT03978520
Principal Investigator: David H. Goddard.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.